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ABSTRACT 
 
Increased death rates due to lung cancer have necessitated the search for 
potential novel anticancer compounds such as carbazole derivatives. 
Carbazoles are aromatic heterocyclic compounds with anticancer, 
antibacterial and anti-inflammatory activity. The study investigated the ability 
of the novel carbazole compound (Z)-4-[9-ethyl-9aH-carbazol-3-yl) amino] 
pent-3-en-2-one (ECAP) to inhibit the proliferation of lung cancer cells and its 
mechanism of action. ECAP was synthesized as a yellow powder with melting 
point of 240-247 °C. The 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), lipid peroxidation and comet assays were used to assess the 
anti-proliferative effects of the compound on A549 lung cancer cell line. 
Protein expression was determined using western blots, apoptosis was 
measured by luminometry for caspase-3/7, -8 and -9 and flow cytometry was 
used to measure phosphatidylserine externalisation.  
 
ECAP induced a p53 mediated apoptosis of lung cancer cells by significantly 
down-regulating the expression of antioxidant defense proteins, Hsp70  
(p < 0.02) and Bcl-2 (p < 0.0006), thereby up-regulating reactive oxygen 
species (ROS) production. This resulted in DNA damage (p < 0.0001) and 
subsequent up-regulation of Bax and caspase activity consequently inducing 
apoptosis of lung cancer cells. These results demonstrate the potential 
anticancer effects of ECAP on cultured lung cancer cells. However, further 
investigation and characterization is required to fully understand the possible 
use of carbazole compound (Z)-4-[9-ethyl-9aH-carbazol-3-yl) amino] pent-3-
en-2-one as potential lung cancer treatment.  
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   1	  
INTRODUCTION 
Cancer is the second leading disease after cardiovascular diseases 
worldwide, accounting for high mortality rates (Bello et al., 2011). According to 
Globocan the global new cancer cases and cancer related deaths increased 
from about 12,7 million and 7,6 million in 2008 to 14,1 million and 8,2 million 
in 2012 respectively. Lung cancer is the main cause of cancer related deaths 
worldwide with more than million deaths each year (Jemal et al., 2004). Most 
of global cancer cases are reported in developing countries, with a high 
mortality rate of 63% (Ferlay et al., 2010). An increase in cancer cases such 
as lung cancer in developing countries such as South Africa (SA) are 
associated with infectious diseases like Human Immunodeficiency Virus 
(HIV)/Acquired Immunodeficiency Syndromes (AIDS) and tuberculosis (TB) 
(Bello et al., 2011).  During 2006 alone about 4 525 lung cancer related 
deaths were reported in SA.  In addition increased lung cancer cases in SA 
are also attributed to other factors such as smoking, environmental pollutants, 
occupational exposure and changing lifestyles (Bello et al., 2011).   
 
Reactive oxygen species (ROS) are one of the major causes of malignancy. 
They are products of oxygen metabolism in cells and their functions range 
from cell signaling, homeostasis and antimicrobial effects (Uttara et al., 2009). 
Mammalian cells are continually exposed to ROS generated both extrinsically 
and intrinsically (Pelicano et al., 2004). Chronic and persistent exposure to 
high ROS levels induces DNA, protein and lipid damage, and can result in 
induction of diseases such as cancer (Waris and Ahsan, 2006).  
	   2	  
Cellular homeostasis in multicellular organisms is strictly maintained through 
regulation of cell proliferation and cell death by the cell cycle and apoptosis.   
 
The cell cycle is a tightly regulated process under the control of specialized 
regulatory molecules such as cyclins and cyclin dependent kinases (CDK). 
However, mutation of tumor suppressor genes like p53 and elevated levels of 
ROS may allow for unregulated growth leading to cancer development. 
Mammalian cells contain defense systems to regulate oxidative damage, and 
these include proteins such as superoxide dismutase (SOD), nuclear factor 
erythroid 2-related factor 2 (Nrf2) and heat shock protein 70 (Hsp70) (Scherz-
Shouval and Elazar, 2011, Whitacre et al., 1999, Suzuki et al., 2013)  .  
 
Different therapies including chemotherapy, surgery and radiotherapy have 
been used for cancer treatment. However, chemotherapy and radiotherapy 
lack specificity therefore healthy cells can also be harmed during treatment, 
also the survival rates for lung cancer patients undergoing surgery is poor 
(Cavendish, 2008). There are no effective treatment drugs for lung cancer, 
hence there is need for more potent anti-lung cancer drugs. The challenge still 
is the ability to develop highly effective drugs specific for lung cancer with 
slight or no side effects on normal cells.  
 
Heterocycles are aromatic molecules joined in a ring that consists of at least 
one element other than carbon. These compounds have become an important 
class of organic compounds for research because of their numerous medical 
and agricultural applications (Liu and Larock, 2007).  
	   3	  
Carbazoles are aromatic heterocyclic organic compounds, with a tricyclic 
structure comprising of two benzene rings each fused onto a five-structured 
nitrogen-containing ring (Liu and Larock, 2007, Nandy et al., 2014).  
 
These synthetic or natural products function through interaction with the DNA; 
they damage DNA resulting in inhibition of synthesis of new DNA or RNA 
(Roy et al., 2005). Carbazoles and their derivatives inhibit cancer growth by 
intercalating into DNA, inhibiting DNA topoisomerase II activity, as well as 
through covalent DNA adducts formation, which are mediated through 
oxidation by cytochrome P450 and peroxides (Nandy et al., 2014).  
 
Different natural and synthetic carbazole derivatives including elipticine, 
elivacine, elliptinium acetate, mahanimbine, eukonine, koenoline and 
rebaccamycin have been reported to have antineoplastic activity (Nandy et 
al., 2014). Based on their reported anti-tumour, antibacterial and  
anti-inflammatory activities, different synthetic carbazole analogs have been 
synthesized from naturally occurring carbazoles (Liu and Larock, 2007, Nandy 
et al., 2014). Carbazoles and their derivatives are increasingly being targeted 
for potential use in cancer treatment owing it to their large π-conjugated 
system, which make it easy to introduce different functional groups into the 
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AIM AND OBJECTIVES 
 
The primary goal of the study was to investigate the anti-proliferative 
properties of a novel synthesized carbazole compound (Z)-4-[9-ethyl-9aH-
carbazol-3-yl) amino] pent-3-en-2-one (ECAP) on A549 lung cancer cell line. 
 
The objectives were: 
1. To determine the cytotoxicity of ECAP using MTT assay. 
2. To examine the genotoxic effect of ECAP on A549 cells using comet 
assay. 
3. To establish the effect of ECAP on ROS production in A549 lung 
cancer cell line. 
4. To investigate the effect of treating A549 lung cancer cells with ECAP 
on the expression of anioxidant, apoptotic and anti-apoptotic 
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CHAPTER ONE 
1.1. LITERATURE REVIEW 
1.1.1. Cancer biology 
The work of previous scientists including Mendel, Darwin, Watson and Crick 
has provided us with a foundation to understand different fields of molecular 
biology, genetics as well as medical and cancer research (Weinberg, 2014).  
It all started in the early 19th century when Gregor Mendel established the 
basic rules of genetics through characterization of pea plants. It was through 
the light of his principles of genetics and mutation that further helped with 
explaining the Darwinian principles of evolution and how mutations are 
responsible for the change in genetic information of the gene, thereby altering 
the characteristics of the affected allele (Weinberg, 2014).  
 
These mutant alleles can then be passed from parent to the offspring; 
however mutations found in the somatic cells are not transmitted to the 
offspring and can give rise to a number of diseases such as cancer. Tumour 
cells arise from many specialized cells in the human body. The formation of 
the human body is governed by the cell cycle and division which give rise to 
tissues; tissues in turn results in the formation of organs which form the 
human body (Figure 1) (Almeida, 2010). 
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Figure 1: The seven hierarchal levels of organisation forming the body 
 (http://anaphysiology.blogspot.com/) 
 
1.1.1.1. Cell cycle 
 
Cell division is an essential component for the development and growth of 
organisms. It is governed by a series of events known as the cell cycle; a 
process tightly regulated by regulatory proteins known as cell-cycle control 
system, which ensure that the integrity of the organism is maintained (Park 
and Lee, 2003, Novák and Tyson, 2004). Loss of cell cycle regulation can 
result in uncontrolled cell growth, the main characteristic essential for cancer 
formation (Almeida, 2010).  The main function of the cell cycle is to ensure 
accurate genomic duplication and chromosome segregation into each 
daughter cell (Almeida, 2010, Alberts et al., 2008).  
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The eukaryotic cell cycle consists of G1 and G2 Gap phases, DNA synthesis 
phase (S phase), M phase (mitosis/ meiosis) and the arrested or quiescent 
phase (G0 phase) Figure 2 (Park and Lee, 2003, Tyson and Novak, 2001). 
The G1, S and G2 phases collectively form the interphase, whereby the cell 
function normally and prepare itself for division. 
 
 
Figure 2: The five phases of the cell cycle 
 (http://www.bdbiosciences.com/research/apoptosis/analysis/index.jsp) 
 
Depending on the environment and cell growth signals, cells may remain in 
G1 or may leave the cell cycle temporarily or permanently and enter the G0 
phase. However, during cell division, the cell enters G1 and progress to the S 
phase for chromosome replication (Almeida, 2010, Alberts et al., 2008). The 
cell then moves to G2 phase where it increases its size and develops more 
components preparing itself for division. If the DNA is correctly synthesized it 
progresses to the M phase where it divides producing two daughter cells.  
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The newly synthesized daughter cells will then enter the G1 phase. On 
average the human cell cycle process takes 12-24 hours of which 
approximately 30 minutes to one hour is spent at the M phase (Almeida, 
2010).  
 
1.1.1.1.1. Regulation of the cell cycle 
 
Each stage of cell cycle consists of checkpoints whereby the cycle is 
temporarily halted until certain conditions are met. The cell cycle process is 
dependent on activation and inactivation of cyclin-dependent kinases (CDKs), 
the small serine/threonine protein kinases whose activity phosphorylates the 
intracellular proteins essential for the regulation of the cell cycle (Almeida, 
2010, Alberts et al., 2008, Park and Lee, 2003, Rastogi and Mishra, 2012).  
CDKs activity is regulated by tightly binding to the cyclins (Alberts et al., 
2008).  
 
The four classes of cyclins are: (1) G1/S-cyclins which activates the CDKs in 
the late G1 phase initiating the start of cell cycle and their levels drop in the  
S-phase, (2) S-cyclins, which bind to the CDKs activating chromosome 
replication. S-cyclin remains active until mitosis. (3) M-cyclins activate CDKs, 
which initiate the entry into the M-phase at the G2/M checkpoint, and the (4) 
G1-cyclins that regulate the activity of G1/S cyclins. CDK activity is suppressed 
by inhibitory phosphorylation and CDK Inhibitory Proteins (CKIs) (Alberts et 
al., 2008). In cancer cells, genes encoding CDKs, CDK-activating enzymes, 
cyclins and checkpoint proteins are mutated thus resulting in overexpression 
of proteins such as CDKs and cyclins (Vermeulen et al., 2003).  
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CDK and cyclin overexpression is evident in various human cancers (Park 
and Lee, 2003). Overexpression of cyclin A and cyclin E has been reported in 
lung carcinoma (Dobashi et al., 1998).  
 
1.1.2. Cancer formation 
 
The word cancer was introduced around 460 – 370 BC by Hippocrates the 
Greek physician, and it is used to describe the disease characterized by 
unregulated proliferation (Figure 3) and the ability to spread into other body 
parts (Almeida, 2010). Over hundred different types of cancers have been 
identified and they are classified into carcinomas, sarcomas, leukaemias and 
lymphomas depending on the tissue from which they originate (Alberts et al., 
2008).  Majority of human cancers (about 90%) are carcinomas, which are 
cancers arising from epithelial cells. Sarcomas are less common and they 
arise from connective tissue, bone, fat or muscle, while leukemias and 
lymphomas arise from white blood cells (Alberts et al., 2008, Almeida, 2010). 
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Figure 3: An overview of cancer formation from loss of normal growth control 
 (http://www.petcancercenter.org/About_Cancer_Main_Page.html) 
 
1.1.3. Cancer cases 
 
Majority of global cancer cases are reported in developing countries such as 
South Africa (SA), with 63% mortality rate (Ferlay et al., 2010). This is due to 
poverty, lack of knowledge, poor health facilities, lack of trained health 
professionals and late diagnosis. Majority of cancers in developing countries 
are diagnosed at an advanced stage due to late detection, thus account for 
poor survival after diagnosis. Commonly reported cancers include breast (1,7 
million, 11.9%), lung (1,8 million, 13%) and colorectum (1.4 million, 9.7%).  
 
1.1.3.1. Lung cancer 
 
Lung cancer is an important form of cancer worldwide accounting for 1.4 
million (18.2%) deaths (Ferlay et al., 2010).   
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Lung cancer is a malignant tumour of the lung characterized by uncontrolled 
cell proliferation in the lung tissues. The two main types of lung cancer include 
the non-small cell lung cancer (NSCLC) and the small cell lung cancer 
(SCLC) (Almeida, 2010). NSCLC accounts for about 85% of lung cancers 
(Parsons et al., 2010). NSCLC is further characterized into squamous cell 
carcinoma which is the commonly known type of NSCLC originating from the 
bronchial tubes, adenocarcinoma found in the mucus producing lung glands, 
bronchio-alveolar carcinoma which starts close to the air sacs and large-cell 
undifferentiated carcinoma which forms from near the outer edges of the lung. 
 
1.1.3.1.1. Risk factors associated with lung cancer development 
 
Lung cancer development is attributed to by many factors such as DNA 
damage, epigenetic changes which can invade cellular processes including 
proliferation, DNA repair and apoptosis as well as family history of the 
disease. However, tobacco smoking is reported to be the main cause of lung 
cancer and it accounts for 80-90% of lung cancer cases (Figure 4) (Almeida, 
2010). Lung cancer development can also be caused by environmental 
pollutants such as exposure to radon, an odourless, invisible radioactive gas 
capable of inducing DNA damage as well as asbestos responsible for 
development of mesothelioma, a form of lung cancer originating in the lining 
of the lung (Almeida, 2010).  
 
Developing countries are reported to have a correlation between TB, HIV, 
smoking and chronic obstructive pulmonary diseases (COPD) (Acehan et al., 
2002). 
	   12	  
 There is also an increasing number of parasitic and bacterial infections which 
are associated with cancer development. The relationship between lung 
cancer and TB has been associated with the ability of lung cancer treatment 
to activate latent M tuberculosis (Marais et al., 2013). There is an increase in 
lung cancer risk in HIV infected young people with a long history of tobacco 
smoking (Remick, 1992, Slee et al., 1999). 
 
 
Figure 4: An image of (a) health lung and (b) cancerous lung 
(http://cancerssymptoms.org/lung-cancer) 
 
1.1.3.1.2. Types of treatments 
 
The three standard cancer treatment strategies include surgery, 
chemotherapy and radiation. Surgery is a commonly used technique at an 
early stage of cancer and it involves the removal of the primary tumour.  
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Early detection of lung cancer is suggestive of lobectomy, which involves the 
removal of the entire lobe.  
Other surgical techniques for lung cancer treatment include wedge resection 
or segmentectomy, that is used to remove a portion of the malignant tissue in 
a lobe and pneumonectomy which, is the removal of the entire lung (Almeida, 
2010).  
 
Chemotherapy is a standard form of cancer therapy, which is used to prevent 
cancer cells from multiplying. Typical chemotherapy drugs used for NSCLC 
include carboplatin or cisplatin, which is used in combination with paclitaxel 
(Almeida, 2010). However, chemotherapy can be harmful to healthy cells 
resulting in serious side effects (Cavendish, 2008); as a result there is a need 
for development of more target specific and effective anti-cancer drugs.  
 
Radiotherapy is another form of lung cancer treatment which uses high 
energy radiation targeted at cancerous tissue. The high energy radiation 
permanently damages the DNA of cancerous cells resulting in their death 
(Cavendish, 2008). Radiotherapy can be performed from inside the body 
(internal radiotherapy) or from outside the body (external radiotherapy). 
Radiotherapy can be used together with surgery and/or with chemotherapy to 
reduce the tumour size relieving pain and bleeding, as well as for opening air 
passages to enhance air flow in the lung (Almeida, 2010). The side effects of 
radiotherapy include sore skin, tiredness, hair loss and it takes time for the 
beneficial effects to be apparent.  
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Nonetheless, just like chemotherapy, radiation therapy is not specific and it 
damages both cancer and non-cancer cells (Cavendish, 2008).  
Therefore there is need for the discovery of new therapeutic drugs for lung 
cancer, which are effective, specific and with less side effects.  
 
1.1.4. Reactive Oxygen Species 
 
Reactive oxygen species (ROS) are oxygen containing free and non-radical 
molecules including: hydroxyl radical (HO.), superoxide anion (O-2), hydrogen 
peroxide (H2O2) and hypochlorite anion (OCl-.). They are extremely unstable 
and react readily with other molecules. They are formed through a number of 
mechanisms, which include cellular respiration, and also they are synthesized 
by phagocytic cells like neutrophils and macrophages (Figure 5) (Li et al., 
2011, Uttara et al., 2009). Their production is essential for conducting cellular 
biochemical activities including signal transduction, muscular proliferation, 
gene transcription and killing of microbes (Uttara et al., 2009). Humans are 
also exposed to ROS from environmental factors including pollution and 
cigarette smoke.  
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Figure 5: The effect of ROS overproduction (Castello et al., 2010). 
	  
1.1.4.1. Cellular defense against ROS 
 
ROS are strong oxidants and can damage cells structures and other cellular 
molecules.  Eukaryotic cells possess antioxidant defense systems, which 
include superoxide dismutase, catalases, glutathione peroxidase and 
glutathione reductase that are known to reduce free radicals to less harmful 
species in order to ensure cellular homeostasis. The anti-oxidants provide 
electrons to free radicals in order to neutralize them. There is need for a 
balance between production of ROS and that of anti-oxidant defenses.  
 
Down-regulation of antioxidant defense systems and overproduction of ROS 
induce oxidative stress, which damages biomolecules, which include proteins, 
DNA and lipids. The resulting oxidative damage is associated with formation 
of chronic diseases such as carcinogenesis (Uttara et al., 2009).  
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Different cancer cells consists of elevated ROS levels compared to non-
cancer cells, as a result ROS over-production can be used as a selective 
tumor suppressor in cancer treatment (Behrend et al., 2003, Hileman et al., 
2004, Toyokuni et al., 1995).  
 
1.1.4.1.1. Keap-1/Nrf2 Pathway 
 
Keap-1/Nrf2 pathway is one of the key regulators of the cytoprotective 
responses to oxidative damage (Kansanen et al., 2013, Zoja et al., 2014). 
Nrf2 (nuclear factor erythroid 2-related factor 2) is the primary antioxidant 
response regulatory protein belonging to the Cap’n’Collar subfamily of the 
bZIP transcription factors (Velichkova and Hasson, 2005, Taguchi et al., 2011, 
Tufekci et al., 2011). It is an important protein essential for defense system 
against oxidative stress, thus maintaining the redox balance in the cell (Zoja 
et al., 2014). Under normal cell conditions Nrf2 is bound to the cystolic 
repressor protein Keap1 (Kelch ECH associated protein 1) which maintain 
Nrf2 in the cytoplasm, thus activating its ubiquitin-mediated degradation 
(Kansanen et al., 2013, Zoja et al., 2014, Nguyen et al., 2009). 
 
Activation of Nrf2 stimulates the anti-inflammatory and antioxidant response 
and activation of Keap1 represses Nrf2 activation. Upon exposure to oxidative 
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In the nucleus NRF2 forms a heterodimer with small Maf protein, binding to 
the antioxidant response elements (ARE) at the promoter regions of cellular 
defense enzyme genes, thereby promoting their transcription (Figure 6) 
(Nguyen et al., 2009, Zoja et al., 2014, Kansanen et al., 2013, Velichkova and 
Hasson, 2005). Although Nrf2 is important in cancer chemoprevention in 
normal tissues, in malignant cells Nrf2 enhances their chemo resistance 
thereby increasing tumour growth (Sporn and Liby, 2012). Lungs are 
respiratory organs characterized by elevated Nrf2 levels. This high Nrf2 
concentration is what makes lung cells resistant to high levels of ROS 
produced during respiration. It has been reported that Nrf2 can induce A549 
lung cancer cells proliferation (Mitsuishi et al., 2012). 
 
 
Figure 6: Nrf2/Keap1 signaling pathway (Lakhan et al., 2009). 
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1.1.4.1.2. Superoxide dismutase (SOD) 
 
SOD are a group of anti-oxidant enzymes that activates superoxide anion  
(O2-) dismutation into a molecular oxygen or hydrogen peroxide. The resulting 
products are further converted into molecular oxygen and water by catalase 
thus ensuring that the cellular O2- are under physiological conditions (Pelicano 
et al., 2004). The three different types of SOD are classified according to their 
protein fold structure and metal cofactor. They include copper-zinc SOD found 
in mammals, manganese-iron SOD found in mitochondria and bacteria and 
nickel SOD present in prokaryotes.  
 
Humans and other mammals possess three types of SOD which are localized 
in different compartments, SOD1 is a copper –zinc SOD found in cytoplasm, 
SOD2 is a mitochondria localized manganese SOD and SOD3 is an 
extracellular copper zinc SOD (Alscher et al., 2002, Abreu and Cabelli, 2010).  
 
1.1.4.1.3. Heat shock protein70 (Hsp70) 
 
Hsps are a large family of conserved proteins primarily functioning as 
molecular chaperones (Mayer and Bukau, 2005, Castelli et al., 2004). Heat 
shock protein 70 (Hsp70) is a 70-kDa protein essential for the folding of the 
newly synthesized proteins, protein translocation and refolding of misfolded 
and/ or aggregated proteins. They are involved in cellular protection against 
oxidative stress.(Castelli et al., 2004, Mayer and Bukau, 2005, Feng et al., 
2006).  
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Overexpression of Hsp70 is induced by a number of stress stimuli through 
stress-activated protein kinase (SAPK) and mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling cascades 
(Juhasz et al., 2013). Hsps are able to promote cell growth, suppress 
senescence and inhibit stress induced apoptotic pathways; as a result Hsp70 
overexpression has been reported in various cancer cells including NSCLC 




Apoptosis is a programmed cell death employed by the cell or organism for 
development and as a host defense mechanism (Chang and Yang, 2000).  
It is responsible for elimination of damaged cells thus maintaining cellular 
homeostasis. Cells undergoing apoptosis are characterized by a series of 
morphological characteristics such as cell shrinkage, plasma membrane 
blebbing, DNA fragmentation and chromatin condensation (Chang et al., 
2013, Wu, 2001, Wong, 2011).  
 
Apoptotic cells can be further characterized by biochemical features which 
include expression of surface markers such as phosphatidylserine (PS), the 
recognition ligand functioning as a signal for macrophages to phagocytose 
dying cells (Elmore, 2007). PS is a negatively charged phospholipid located 
inside the plasma membrane. Its translocation can be detected using Annexin 
V protein which has a high affinity for PS (Hingorani et al., 2011).  
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In order to develop novel and effective anticancer compounds to treat different 
cancers including lung cancer, understanding the pathways of apoptosis is 
crucial. This is mainly because most anticancer treatments exert their 
cytotoxicity to different cancer cells through the apoptotic pathway. Activation 
of a family of cysteinyl-aspartate proteases (caspases) is one of the main 
signaling cascades involved in apoptotic pathway (Chang and Yang, 2000).  
1.1.5.1. Caspases 
 
Caspases are a group of enzymes involved in pathways essential for 
maintaining cellular homeostasis based on their regulation of cell death and 
inflammation. They are synthesized as inactive zymogens or precursors, 
which are activated through proteolytic cleavage (Beere, 2005, Parrish et al., 
2013, Chang and Yang, 2000, McIlwain et al., 2013).  
The primary structure of caspases is composed of an amino-terminal pro-
domain and a carboxy-terminal protease domain containing the cysteine 
residue (Parrish et al., 2013). Based on their position in the apoptotic 
signaling pathway, caspases are grouped into initiator or inducer caspases 
(caspase-2, -8, -9 and -10) and effector caspases (caspase-3, -6 and -7).  
 
The initiator caspases are characterized by longer amino-terminals and are 
activated through dimerization with adaptor molecules (Muzio et al., 1998, 
Chang et al., 2003, Boatright et al., 2003, Pop et al., 2006). Effector or 
executioner caspases have shorter pro-domains and are responsible for 
proteolytic degradation of targeted proteins leading to cell death.  
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Effector caspases activation is executed by proteolytic cleavage between the 
small and large subunits by initiator caspases (Parrish et al., 2013, Riedl and 
Shi, 2004).  
 
1.1.5.1.1. Caspases and apoptosis 
 
Apoptosis is initiated through the intrinsic (mitochondrial) and extrinsic (death 
receptor) pathways based on the exerted signal and caspases activated 
(Figure 7). The relationship between caspase activity and apoptosis was 
previously demonstrated on A549 lung cancer cells whereby polyporenic acid 
inhibited cell proliferation of A549 cells through a caspase-8-mediated 
apoptosis (Ling et al., 2009). 
 
 
Figure 7: Schematic diagram of apoptosis, showing both extrinsic and intrinsic apoptotic 
pathways. 





1.1.5.1.1.1. The extrinsic apoptotic pathway: death receptor pathway 
 
The extrinsic apoptotic pathway is a ligand-induced pathway, which involves 
activation of death receptors at the plasma membrane in order to remove 
unwanted cells in growing organisms. The pathway is initiated when an 
extracellular death ligand bind to a death receptor at the cell surface.  
Commonly reported death receptors include tumour necrosis factor receptor 
type 1 (TNFR1) superfamily and its related protein Fas (also known as CD95 
or APO-1) (Hengartner, 2001, McIlwain et al., 2013). A typical structure of 
these death receptors consists of an extracellular region with cysteine-rich 
domains (CRDs), which are essential for ligand binding and an intracellular 
region containing a death domain (DD).   
 
Upon ligation of death receptor ligand and death receptor, oligomerization is 
induced at the cell surface resulting in the formation of death-inducing 
signaling complex (DISC) (Boatright et al., 2003, Wachmann et al., 2010).  
The adaptor proteins including: Fas-associated death domain (FADD) and 
TNF-related (TNFR) associated death domain (TRADD) are then recruited to 
the cytoplasmic tail (Algeciras-Schimnich et al., 2002). FADD and TRADD 
then recruit caspase-8 zymogens by forming a homophilic interaction with 
their N-terminal death effector domains (DEDs) (Kischkel et al., 1995, 
McIlwain et al., 2013). 
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This activates dimerization and activation of caspase-8. Depending on cell 
type, caspase-8 activation by the DISC may result in subsequent cleavage 
and activation of downstream caspases (caspase-3 and -7) thus inducing 
apoptosis. However, for other cells including type II cells mitochondrial 
induced apoptotic signal is essential for a cell to undergo apoptosis.  
 
1.1.5.1.1.2. The intrinsic apoptotic pathway: mitochondrial-mediated 
                   pathway. 
 
This pathway is triggered by a vast array of internal stimuli such as DNA 
damage, accumulation of unfolded proteins, mitochondrial damage and 
cytotoxic drugs (McIlwain et al., 2013). Caspase-9 is responsible for the 
initiation of this pathway. The intrinsic mitochondrial-mediated apoptotic 
pathway involves mitochondrial polymerization which results in release of 
cytochrome c into the cytoplasm and pro-caspase-9 activation (Wong, 2011). 
The pathway is tightly regulated by Bcl-2 family of proteins which are 
classified into anti-apoptotic proteins and pro-apoptotic proteins (Tsujimoto et 
al., 1984). The pro-apoptotic proteins are responsible for induction of 
mitochondrial polymerization and the release of cytochrome c.  
 
The released cytochrome c then interacts with the adaptor protein known as 
Apaf-1 (apoptotic protease activating factor-1) resulting in the formation of the 
heptameric backbone of the apoptosome complex (Liu et al., 1996, Zou et al., 
1997, Acehan et al., 2002). The apoptosome complex is a seven-spoked 
wheel consisting of a central hub with a caspase-9 recruitment domain 
afforded by the caspase-activating recruitment domain (CARD) of Apaf-1.  
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As a consequence the apoptosome induces conformational change                                                                                                              
consequently recruiting and activating the initiator caspase-9 through 
dimerization (McIlwain et al., 2013). The activated caspase-9 subsequently 
cleaves and activates the downstream effector caspases such as caspase-3 
and -7 which execute apoptosis through proteolytic cleavage of proteins such 
as PARP-1 thereby inducing cell death (Slee et al., 1999).   
1.1.6. p53  
 
p53 is a DNA-binding phosphoprotein with a molecular weight of 53 kDa (Bai 
and Zhu, 2006, Wong, 2011). It was firstly identified around 1978 (Bai and 
Zhu, 2006, Linzer and Levine, 1979, DeLeo et al., 1979, Lane and Crawford, 
1979). Initially p53 was thought to be weakly oncogenic, however later work 
showed its oncogenic property was found to have resulted from a p53 
mutation which was then later called ‘guardian of the genome’ (Bai and Zhu, 
2006, Sigal and Rotter, 2000).  
 
1.1.6.1. The structure of p53 
p53 is a tumour suppressor protein normally existing as a homotetramer or as 
a complex of tetramers (Bellamy, 1997). It is encoded by TP53, the tumour 
suppressor gene and is a member of a highly conserved protein family 
consisting of two other members: p63 and p73 (Kaghad et al., 1997, Schmale 
and Bamberger, 1997). The structure of the wild-type p53 (wt p53) protein 
consists of 393 amino acids, with an N-terminus consisting of an amino-
terminal domain of about 1-42 residues, and a proline-rich region (61-94 
residues) (Vousden and Lu, 2002, Slee et al., 2004, Bode and Dong, 2004a). 
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The C-terminal region (301-393 residues) contains an oligomerization domain 
(324-355 residues), a nuclear localization signal (NLS) sequence, carboxyl-
terminal regulatory domain (363-393 residues) and three nuclear export signal 
(NES) sequence (Figure 8).  
 
 
Figure 7: The representation of the p53 structure (Bai and Zhu, 2006). 
 
The amino-terminal region of p53 is essential for transactivation, and it is a 
point of interaction with transcription factors such as MDM2 (murine double 
minute 2) or Hdm2 (in humans) (Lin et al., 1994, Fields and Jang, 1990). The 
proline region is essential for p53 stability which is regulated by MDM2 
(Sakamuro et al., 1997).  
The central core of p53 contains a consensus sequence known as the DNA 
binding domain required for the sequence-specific DNA binding (Kern et al., 
1991).  
 
1.1.6.2. The physiological functions of p53 
 
p53 is a regulatory protein responsible for regulating expressions of different 
targeted genes in response to insults present in the cell and the environment. 
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It is involved in pathways, which control uncontrolled cell proliferation in order 
to maintain genome integrity after genotoxic stress (Vousden and Lu, 2002, 
Vogelstein et al., 2000). P53 is a sequence specific transcription factor and a 
tumour suppressor protein, which is commonly, mutated in human cancers 
(Beckerman and Prives, 2010, Bellamy, 1997).  
The protein DNA binding domain of p53 is responsible for over 80% of 
cancer-derived p53 mutations (Olivier et al., 2002).  
 
p53 mutation is accounted to by factors including its sensitivity to single base 
change in the coding sequence and change in phenotype due to loss of allele 
(Bellamy, 1997). This protein plays an important role in inhibition of 
tumorigenesis through regulation of cell cycle, differentiation, development, 
gene amplification, chromosomal segregation, DNA recombination, 
senescence and induction of apoptosis (Murray-Zmijewski et al., 2008, 
Vousden and Lu, 2002, Oren and Rotter, 1999).  
 
1.1.6.3. Regulation of p53 levels and activity 
 
Under normal cell conditions Mdm2 maintains wt p53 at low concentrations as 
well as in an inactive form. Mdm2 is a negative regulator of p53, which 
interacts with p53 at the N-terminus thus inhibiting its transcriptional activity 
(Chen et al., 1994, Brooks and Gu, 2003). Furthermore, Mdm3 has been 
reported to translocate p53 from the nucleus to the cytoplasm for ubiquitin-
mediated degradation (Freedman and Levine, 1998).  
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However, various stimulus such as DNA damage, hypoxia and heat shock 
result in p53 activation. p53 activation follows three steps: stabilization, 
sequence specific DNA binding and transcriptional activation of target genes 
(Figure 9) (Yee and Vousden, 2005).  
 
Figure 8: Schematic representation of p53 activation. (Bode and Dong, 2004b). 
 
During p53 stabilization, DNA damage induces post-translational 
phosphorylation of p53 at the amino terminus thus disrupting the Mdm2-p53 
interaction and activating p53.   
	   28	  
p53 phosphorylation and acetylation upon genotoxic stress enhance 
transcriptional activation of p53 resulting in its stabilization and accumulation 
in the nucleus (Appella and Anderson, 2001, Xu, 2003). Phosphorylation of 
p53 at Ser46 in tumour cells induces p53-mediated activation of apoptotic-
targeted genes (D'Orazi et al., 2002, Bai and Zhu, 2006). 
1.1.6.4. p53 and cell cycle 
 
DNA damage induces activation of ataxia-telangiectasia mutated (ATM), 
which in turn activates checkpoint kinase 2 (Chk2) kinase (Matsuoka et al., 
1998). Both ATM and Chk2 consequently result in p53 phosphorylation 
inducing cell cycle arrest or apoptosis (Banin et al., 1998, Canman et al., 
1998). Activated p53 is able to induce cell cycle arrest in the G1, G2 and S 
phases within the cell cycle (Agarwal et al., 1995).  
 
p53 induces cell cycle arrest at  G1 and G2 phases to provide the cell with an 
additional time to repair genomic damage prior to entering the important 
stages of DNA synthesis and mitosis. During cell cycle arrest, the p53 
biochemical functions releases the arrested cells back into the proliferation 
pool, thus allowing for DNA repair processes such as base excision repair and 
nucleotide excision repair (Zhou et al., 2001). Upon cellular stress, p53 
induces G1 arrest through transcriptional activation of the cyclin-dependent 
kinase inhibitor, p21 (el-Deiry et al., 1993, Chen et al., 1996).  
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1.1.6.5. p53 and apoptosis 
 
In the case whereby DNA damage is too severe to be repaired, p53 induces 
apoptosis of cell with damaged DNA. A p53-dependent apoptosis was first 
reported in 1993 after irradiation of mouse thymocytes by Clarke and co-
workers and also by Lowe and co-workers (Zilfou and Lowe, 2009, Clarke et 
al., 1993). The ability of p53 to regulate cell cycle and to induce of apoptosis 
has resulted in the increased enthusiasm to study its properties as a potential 
target for anticancer therapy. p53-mediated apoptosis is based on p-53 
localization to the mitochondria where it modulate the expression of targeted 
proteins such as the Bcl-2 family of proteins which control mitochondrial 
permeability (Bai and Zhu, 2006).  
 
1.1.1.6. Bcl-2 family of apoptosis and apoptosis 
 
Bcl-2 family of proteins consists of proteins with both cell-damage and cell-
survival signals. Bcl-2 was the first protein to be identified in this family and it 
obtained its name from B-cell lymphoma/leukaemia-2, the human B-cell 
proteins capable of chromosomal translocation (Kroemer et al., 2009, Vaux 
and Silke, 2003, Tsujimoto et al., 1984). Bcl-2 proteins are dimers located on 
the outer mitochondrial membrane and they are responsible for induction of 





	   30	  
Over 25 members of Bcl-2 proteins have been identified and based on their 
function and Bcl-2 homology (BH) they are broadly divided into three groups:  
the anti-apoptotic proteins (Bcl-2 and Bcl-XL) which contain four BH domains, 
pro-apoptotic proteins (Bax, Bak and Bcl-XI) also containing four BH domains 
and pro-apoptotic “BH3-only” proteins (Bid, Bad, Noxa and Puma) (Haupt et 
al., 2003). In addition to the BH domains, Bcl-2 protein family also consists of 
a carboxy-terminal hydrophobic domain responsible for membrane 
localization (Adams and Cory, 1998, Green and Reed, 1998).  
 
Bcl-2 is a 25-26 kDa protein residing in the cytoplasmic face of mitochondrial 
outer membrane and its primarily function is to protect the mitochondrial 
membrane integrity (Miyashita and Reed, 1995, Petros et al., 2004). Bax is a 
Bcl-2 homolog of 21 kDa and it is mainly localized in the cytosol (Miyashita 
and Reed, 1995, Petros et al., 2004).  During cellular stress such as DNA 
damage, p53 is activated thereafter activating and inducing Bax localization to 
the mitochondrial membrane resulting in increased mitochondrial membrane 
permeability. This results in cytochrome c release and the subsequent 
induction of apoptosis through activation of down-stream apoptotic target 




For over a century, heterocycles have remained an important class of organic 
compounds forming a classical division of organic chemistry research.  
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Their structural flexibility has resulted in their increased use in different fields 
including medicine, agriculture and industry (Dua et al., 2011, Liu and Larock, 
2007). Among heterocycles, carbazoles alkaloids are a group of natural 
compounds with a growing research interest. 
 
The first carbazole was isolated in 1872 by Graebe and Glazer from coal tar. 
Carbazoles have now been isolated from plant species including Murraya 
Clausena, Micromelum and Glycosmis of the Rutaceae family (Majumdar, 
2011). Based on their reported pharmaceutical and industrial properties, 
pronounced effort has been dedicated to develop methods for the effective 
synthesis of carbazole compounds and their derivatives.  
Classical methods used for carbazole synthesis include the Graebe-Ullman 
and the Fischer-Borsche processes (Majumdar, 2011, Liu and Larock, 2007). 
Other synthesis techniques include the palladium catalysed procedure and 
the iron-mediated synthesis.  
 
1.1.7.1. The carbazole structure 
 
Carbazoles and their derivatives are a group of nitrogen containing 
heterocyclic compounds (Nandy et al., 2014). They have a tricyclic structure 
with two benzene rings, each attached on either side of a five-structured 
nitrogen containing ring (Figure 10) (Nandy et al., 2014).   
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Figure 9: Carbazole structure 
(http://www.scbt.com/datasheet-214662-carbazole.html) 
 
The carbazole structure is reported to be dependent on the indole structure 
whereby the second ring is attached to the five-membered ring of the indole at 
the 2-3 positions. The increased interest on carbazoles and its derivatives is 
due to its charge and electronic transport properties, and a large  
π-conjugated system which makes it easy to introduce different functional 
groups into a rigid carbazole ring during synthesis (Nandy et al., 2014).  
1.1.7.2. Biological properties of carbazoles 
 
Carbazoles and their derivatives have been reported to have a spectrum of 
pharmaceutical properties, which include: antimicrobial, anti-HIV, anti-arthritis, 
anti-diabetic and anticancer activities(Kongkathip et al., 2005, Kaplancikli et 
al., 2012, Roy et al., 2005). The anticancer activity of carbazoles and its 
derivatives has been associated with the ability of their structures to 
intercalate into the DNA thus inhibiting the activity of DNA topoisomerase II. 
Their anticancer activities can further be attributed to the formation of covalent 
DNA adducts which are mediated by their oxidation with cytochromes P450 
and peroxides (Nandy et al., 2014).  
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Different natural and synthetic carbazole derivatives including elipticine, 
olivacine, elliptinium acetate, mahanimbine, mukonine, koenoline and 
rebaccamycin have been reported to have antineoplastic activity (Nandy et 
al., 2014). 
 
1.1.8 A549 cells 
 
Potential anticancer pharmaceuticals are studied in vitro prior to clinical trials 
using cancer cell models such A549 cell line. A549 cells are squamous, 
adenocarcinomic human epithelial cells developed in 1972 from a cancerous 
lung tissue of a 58-year-old Caucasian male (Praveen and Manoj, 2014). 
A549 cells are characterized by elevated glutathione levels and high HO-1 
gene expression which is involved in their response to oxidative stress 
(Dubrovskaya and Wetterhahn, 1998). A549 cells also have characteristic 
features of type II alveolar cells, allowing A549 cells not only to be used as a 
model for lung cancer, but also as an in vitro model to study human primary 
alveolar epithelial cells (Tian et al., 2009b, Tian et al., 2009a, Dubrovskaya 
and Wetterhahn, 1998). These cells are also commonly used to study the 
toxic and genotoxic effects of environmental pollutants, since lungs are the 
primary biological targets for inhaled toxins (Dubrovskaya and Wetterhahn, 
1998, Lee et al., 1996). If cultured, A549 cells grow as adherent or monolayer 
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CHAPTER TWO 
2.1. MATERIALS AND METHODS 
2.1.1. Materials 
 
Carbazole derivative (ECAP) was synthesized at the Department of Chemistry 
(Durban University of Technology, SA). A549 cells were obtained from 
Highveld Biologicals (Johannesburg, SA).   
Reagents and equipment  
Reagents and equipment Supplier and product number 
BD FalconTM Polystyrene round 
bottomed tubes, 5 ml, 12x75 mm 
style 
Becton Dickson Biosciences, 
Pharmingen, 
San Diego, CA, USA#352054 
FACS flow Becton Dickson Biosciences, 
Pharmingen, 
San Diego, CA, USA 
FACS clean Becton Dickson Biosciences, 
Pharmingen, 
San Diego, CA, USA 
FACS rinse Becton Dickson Biosciences, 
Pharmingen, 
San Diego, CA, USA 
Trypsin EDTA (0.25% 1X) BioWest, France L0931-100 
Trypan blue 0.4% Sigma-Aldrich, South Africa #T8154 
Ethanol MERCK #SAAR2233540LP 
Foetal calf serum, endotoxin free Delta Bioproducts, Highveld 
Biological, Lyndhurst, South Africa 
#14-501-BI 
Tween 20 MERCK #6164500KF 
acetylacetone Sigma # P7754 
indium chloride Sigma # 334065 
ethyl acetate MERCK # SAAR2235020LC 
anhydrous sodium sulphate Sigma # 239313 
methanol MERCK SAAR416080LC 
Eagle’s minimum essential medium Whitehead Scientific (Johannesburg, SA) 
1% L-glutamine Whitehead Scientific (Johannesburg, SA) 
1% penicillin-streptomycin-fungizone Whitehead Scientific (Johannesburg, SA) 
A549 lung cancer cells HIGH VELD 
DMSO MERCK #K42708912 147 
Spectrophotometer Bio Tek µQuant 
gel red Sigma # S5817 
LMP agarose Life technologies # 16520 
NaCl MERCK #SAAR5822320EM 
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Triton X-100 MERCK # 9036-19-5 OR  
EDTA Sigma-Aldrich, South Africa # E9884 
Fluorescence microscope Olympus IXSI 
Cytobuster reagent supplemented 
with phosphate inhibitor 
Roche, cat. no. 04906837001 
protease inhibitor Roche, cat. no. 05892791001 
Bicinchoninic acid assay Sigma, Germany 
p53 Cell Signaling Technology # 2521P 
Nrf2 Cell Signaling Technology # 8882 
SOD Cell Signaling Technology # 4266 
Hsp70 BD Transduction laboratories # BD 
610607 
1 mM Tris Sigma 
Bcl-2 Cell Signaling Technology # 3869 
anti-mouse Abcam # ab97046 
β-actin Abcam # ab8226 
Clarity Western luminal/enhancer 
solution 
BIO-RAD 
Clarity Western peroxide solution BIO-RAD 
Alliance 2.7 image documentation 
system  
UViTech 
caspase-Glo 3/7 reagent Promega 
caspase-Glo 8 reagent Promega 
caspase-Glo 9 reagent Promega 
ATP reagents Promega 
Annexin-V-FLUOS Staining Kit Roche # 11 858 777 001 
BD Accuri™ C6 flow cytometer Becton Dickson Biosciences, 
Pharmingen, 
San Diego, CA, USA 
MDA Sigma-Aldrich, South Africa # 10838-
3 
2-Mercaptoethanol MERCK #4161200 
APS Sigma-Aldrich, South Africa # A3678 
Tris MERCK 77086-1 /108382-0500 
SDS BDH #301754L 
Glycine MERCK SAAR2676600EM 
copper sulphate solution  Sigma-Aldrich, South Africa # C2284 
Bis-acrylamide Sigma-Aldrich, South Africa # A3449 
TEMED MERCK #1.10732.0100 
Thiazoylblue tetrazolium bromide  Sigma-Aldrich, South Africa # M5655 
BSA ROCHE #10735086001  
Cytobuster reagent supplemented with 
phosphate inhibitor 
Roche # 04906837001 
protease inhibitor  Roche # 05892791001 
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2.1.2. Synthesis of (Z)-4-((9-ethyl-9H-carbazol-3-yl)amino)pent-3-en-2-one 
          (ECAP) 
 
A mixture of acetylacetone (1.02 mL, 0.01 mol), 3-amino-9-ethylcarbazole (2.1 
g, 0.01 mol) and indium chloride (0.22 g, 0.001 mol) in ethanol (25 mL) was 
heated under reflux for 5 h (Figure 11). After the reaction was completed, the 
excess of solvent was evaporated. The resulting residue was then dissolved 
in ice/water and extracted with ethyl acetate. Anhydrous sodium sulphate was 
used for drying the combined organic layers. Silica gel column (eluent–
petroleum ether: ethyl acetate (90:10) was then used for purification. The pure 
product was recrystallized from methanol. 
 
Figure 10: The schematic representation of the ECAP:InCl3/Ethanol, reflux,  5h RT. 
 
The title compound (Z)-4-((9-ethyl-9H-carbazol-3-yl)amino)pent-3-en-2-one 
(ECAP) was prepared in good yield by two component reaction under indium 
chloride as promoter structure of the prepared compound. The structure of the 
prepared compound was then studied and characterized using Infrared (IR), 
Hydrogen-1 (1H) and Carbon-13 (13C NMR) spectroscopic techniques. 
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2.1.3. Tissue cell culture  
 
The A549 lung cancer cells were cultured in 25 cm3 culture flasks at 37ºC, 5% 
CO2 in complete culture media (CCM) which consisted of Eagle’s minimum 
essential medium (EMEM) supplemented with 1% L-glutamine, 1% penicillin-
streptomycin-fungizone and 10% foetal calf serum. Cell growth was monitored 
and cell culture medium (CCM) was changed as required. Confluent flasks 
were trypsinized and trypan blue was used for cell numeration.   
 
2.1.4. Cell viability assay 
2.1.4.1. MTT assay 
2.1.4.1.1. Theory 
 
The methyl thiazol tetrazolium (MTT) assay was used in order to determine 
the cytotoxicity of ECAP on A549 lung cancer cells. This is a colorimetric cell 
viability assay based on the reduction of the yellow 3-(4,5-dimethythiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) salt into a purple formazan in the 
mitochondria of viable cells by mitochondrial succinate dehydrogenase, 
Figure 12 (Stockert et al., 2012, Bopp and Lettieri, 2008). The resulting 
formazan is then solubilized with organic solvent (e.g. propan-2-ol (iso-
propanol archaic)) and measured spectrophotometrically.     
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Figure 11: A schematic representation of cytotoxic assays (Held, 2009). 
 
2.1.4.1.2. Method  
 
A549 cells (20, 000 cells/well) were treated in triplicate with different 
concentrations of ECAP (0, 0.01, 0.05, 0.1, 0.25, 0.5, 0.6, 0.7 and 0.8 µg/ml) 
and incubated at 37ºC, 5% CO2 for 24 h in 96-well microtitre plate. Cells 
incubated with CCM/DMSO (dimethyl sulphoxide) were used as vehicle 
control (V control). CCM/MMT solution was prepared by mixing 20 µl MTT (5 
mg/ml in 0.1 M PBS) and 100 µl fresh CCM (per well). After 24 h incubation, 
the media was removed and cells were washed three times with 0.1M 
phosphate buffer saline (PBS) and then CCM/MTT salt solution was added 
into each well and incubated at 37ºC for 4 h.  The supernatant was removed 
and 100 µl/well DMSO was added followed by 1 h incubation at 37ºC.  
	   39	  
The absorbance of the produced formazan was measured at 570 nm and 
reference wavelength of 690 nm using a Bio Tek µQuant spectrophotometer. 
GraphPad Prism V5.0 software was used to plot a concentration-response 
curve that was subsequently used to determine an IC50 value of ECAP on 
A549 cells.  
 
2.1.5. Lipid peroxidation assay for quantification of malondialdehyde 
          (MDA)  
2.1.5.1. Thiobarbituric acid assay (TBARS) 
2.1.5.1.1. Theory 
 
Lipid peroxidation is a chain reaction characterized by hydrogen abstraction or 
oxygen radical addition thus inducing oxidative damage of polyunsaturated 
fatty acids (PUFA) (Repetto et al., 2012). Different byproducts of lipid 
peroxidation including malondialdehyde (MDA) are produced as a result of 
oxidation of PUFAs (Figure 13) (Hodges et al., 1999). The produced MDA is 
known to react with thiobarbituric acid (TBA) in an acid-catalyzed nucleophilic 
reaction producing a pinkish-red chromogen with an absorbance of 532 nm. 
Therefore, thiobarbituric acid assay (TBARS) was used to determine the 
ability of ECAP to induce lipid peroxidation.  
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A549 cell were treated for 24 hr. Thereafter the supernatant of the control, V 
control and ECAP treated cells was transferred into test tubes with 2% H3PO4 
(200 µl), TBA/BHT solution (400 µl) and 7% H3PO4. A positive control of 1% 
MDA and a negative control of 3mM HCl (400 µl) was used. Samples pH was 
checked (pH 1.5) and heated at 100ºC for 15 min. Samples were allowed to 
cool down at room temperature (RT), followed by addition of 1.5 ml butanol, 
vortexed and then allowed to separate into distinct phases. The upper butanol 
phase was aliquoted into 96-well microtitre plate in triplicates.  
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The spectrophotometer was used to measure the optical at 532 nm with 
reference wavelength of 600 nm. The mean of the optical density was 
calculated for each sample and divided by the absorption coefficient of 156 
mM-1 in order to obtain MDA concentration (µM) per treatment.  
 
2.1.6. DNA damage  
2.1.6.1. Comet assay 
2.1.6.1.1. Theory 
 
Comet assay or single cell gel electrophoresis (SGE) is fluorescent 
microscopy-based technique used for detection of DNA damage. Comet 
assay was originally developed in 1984 by Ostling and Johansson and then 
modified by Singh and coworkers in 1988 (Olive and Banáth, 2006). Comet is 
used to describe the pattern of DNA migration during electrophoresis under 
high pH conditions. 
 
 During comet assay cells are encapsulated with a low-melting point agarose 
suspension, lysed under alkaline conditions followed by electrophoresis of 
lysed cells (Enciso et al., 2009, Olive and Banáth, 2006). The comet assay is 
based on the principle that DNA strands containing breaks lose their 
supercoiling capability and migrate towards the anode forming the comet 
head (Figure 14). Therefore, cells containing high levels of damaged DNA will 
have more intense comet tails.  
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The comet assay was used as previously described by (Tiloke et al., 2013), 
with slight modification to determine DNA damage. The 24 h treatments 
(control, V control and ECAP) were prepared respectively followed by removal 
of supernatant, and then trypsinization. About 20 000 cells/treatment were 
dissolved in 1 ml 0.1 M PBS. Two microscope slides (76 × 26 mm) per 
sample were prepared. The first layer of 700 µl, 2% low melting point agarose 
(LMPA, 37ºC) was added towards the frosted end of the microscope slide, the 
second layer of cells (25µl), 1% LMPA (175 µl, 37ºC) and gel red (1.5 µl). The 
third layer of 1% LMPA (250 µl, 37ºC), and then covered with microscope 
cover slides.  
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After adding each layer of the gel, a coverslip (60 × 20 mm) was placed on 
top of the gel and incubated at 4°C for 10 minutes to allow the gel to solidify. 
After solidification, coverslips were removed and the slides were immersed 
into cold lysing solution [2.5 M NaCl, 1% Triton X-100, 1 M Tris, 100 mM 
EDTA, 10% DMSO] and incubated at 4ºC for 1 h. Following lysis, the slides 
were placed into electrophoresis buffer [1 mM Na2EDTA (pH 13), 300 mM 
NaOH] for 20 min, and then electrophoresis was run at 25 V for 35 min.  
 
After electrophoresis, prepared slides were then washed three times for 5 min 
with neutralizing buffer [0.4 M Tris (pH 7.4)]. Slides were then covered with 
coverslips and viewed with a fluorescent microscope (Olympus IXSI inverted 
microscope with 590 nm emission filters and 510-560 nm excitation). For each 
slide, 50 cells were captured and their comet tail lengths were measured in 
µm using Soft imaging system (Life Science-Olympus Soft Imaging Solution 
v5).  
 
2.1.7. Western blot analysis 
2.1.7.1. Theory 
 
Western blot is an electrophoresis technique used for protein separation and 
identification on the basis of molecular weight (Yang and Ma, 2009). 
Separated proteins are then transblotted onto a membrane, and the 
membrane is probed with antibodies specific for the protein of interest. 
Western blot was used to quantify the protein expression of p53, Bax, Bcl-2, 
Nrf2, SOD and Hsp70 in A549 cells. 
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2.1.7.2. Method 
2.1.7.2.1. Sample preparation 
 
Proteins were isolated from A549 cells using Cytobuster reagent 
supplemented with phosphate inhibitor and protease inhibitor. Bicinchoninic 
acid (BCA) assay was used for protein quantification. Proteins were 
standardized to a concentration of 3.966 mg/ml. Standardized proteins were 
then prepared in a 5X Laemmli buffer [0.5M Tris-HCl (pH 6.8), dH2O, glycerol, 
β-mercaptoethanol, 10% SDS, 1% bromophenol blue] (1:4 ratio) and boiled 
for 5 min at 100ºC. Sodium dodecyl sulphate (SDS) is a detergent used for 
protein denaturation and for creating an overall negative charge on the protein 
to allow protein migration through the gel. β-mercaptoethanol is also involved 
in protein denaturation based on its ability to reduce disulfide bonds of 
proteins while glycerol is used to add density to the sample to aid the sample 
to sink to the bottom of the well when loading into the gel.   
  
2.1.7.2.2. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The prepared sample was allowed to cool at RT before loading into the gel. A 
4% stacking gel and 7.5% resolving gels (dH2O, Tris, SDS, Bis/Acrylamide, 
10% Ammonium phosphate sulphide, TEMED (Tetramethylethylenediamine)) 
were prepared. TEMED was added to initiate N,N’-methylene-bis-acrylamide 
mediated polymerization of acrylamide gels. After polymerization, molecular 
weight and samples were added into the gel in duplicates. The gels were then 
electrophoresed for 1 h at 150 V in 7.5 % SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using Bio-Rad compact power supply.  
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2.1.7.2.3. Transfer 
 
Following electrophoresis gels were equilibrated in a transfer buffer consisting 
of: dH2O, Tris, glycine and methanol. Equilibrated gels, membranes and fibre 
pads were prepared into a sandwich between the two electrodes (Figure 15). 
Trans-Blot Turbo Transfer system was then used to transfer the separated 
proteins into nitrocellulose membrane at 20 V for 45 min using the BioRad 
TransBlot Turbo Transfer System (400mA).  
 
After transfer, nitrocellulose membranes were blocked with 3% BSA for 1 h in 
Tris-buffered saline [(TTBS)-NaCl, Tris, KCl, dH2O, Tween 20, pH 7.4)] 
containing 0.5% Tween20.  
 
2.1.7.2.3.1. Transfer method 
 
After the blocking step, membranes were incubated overnight with primary 
antibodies [p53, Nrf2, SOD, Hsp70 and Bcl-2; 1:5,000 in 1% BSA] followed by 
a 5X wash with TTBS. Nitrocellulose membranes were incubated with a 
horseradish peroxide (HRP) conjugated secondary antibodies (RT, 1 h) 
followed by a 5X wash with TTBS (10 min each).  
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A 50:50 (v/v) of Clarity Western luminal/enhancer solution and peroxide 
solution was added onto each electro-blotted nitrocellulose membrane to form 
the antigen-antibody complex (Figure 16). The generated signal was detected 
using the Alliance 2.7 image documentation system (UViTech). Protein 
expression was then analysed using UViBand Advanced Image Analysis 
software v12.14 (UViTech). The obtained data was expressed as fold change 
(FC).  
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β-actin (ab8226; 1:5,000) was used for protein normalization. After viewing 
the probed proteins of interest, membranes were stripped with 5% hydrogen 
peroxide (30 min, 37ºC), washed 1X with TTBS and incubated overnight with 
β-actin (3% BSA, RT). 
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Luminescence-based assays were used to assess the activities of caspase-
Glo 3/7, 8, 9 and ATP. Luminometry is a highly sensitive analytical technique 
commonly used for measuring chemi- and bioluminescent reactions. ATP can 
be extracted from cells assayed with luciferin-luciferase luminometry to 
determine ATP measurements, whereby ATP is a limiting reagent. During 
ATP analysis, the emitted light is proportional to the amount ATP present in 
the sample (Figure 17). Luminometry can also be used to determine the 
caspase activity. This is based on the addition of the caspase reagent that 
lyses cells and thus activating caspase cleavage of the substrate, generating 
a luminescent signal.   The generated luminescent signal is proportional to the 
caspase activity.  
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Following a 24 h treatment with ECAP, A549 cells were trypsinized, adjusted 
to 20 000 cells/well, followed by centrifugation at 3000g x (5 min, RT). 
Supernatant was removed; the cells were then re-suspended in 50 µl 
PBS/well for each treatment and then seeded into an opaque polystyrene 96-
well microtitre plate in six replicates. 
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The manufacture’s guidelines were used for preparing Caspase-Glo 3/7, 8, 9 
and ATP reagents. About 100 µl of reagent was added into specific wells, and 
then incubated in the dark (30 min, RT). The Modulus microplate luminometer 
was used for the subsequent measurement of the luminescence and the 
obtained data was expressed as RLU. 
 
2.1.9. Annexin-V-Fluos assay 
2.1.9.1. Theory 
 
Phosphatidylserine (PS) externalization is a primary characterization of the 
early stage of apoptosis. PS translocation was determined using annexin-V-
Fluos apoptosis detection kit. Annexin V is a 35-36 kDa Ca2+ dependent 
phospholipid-binding protein with high affinity for PS (Hingorani et al., 2011). 
Apoptosis can be detected by flow cytometry using fluorescein isothiocyanate 
(FITC) labeled Annexin V, whereby this fluorescently labeled Annexin V 
specifically binds to the exposed phophatidyl-serine on the surface of 
apoptotic cells (Figure 18) (Hammill et al., 1999, Bossy-wetzel and Green, 
2000).  
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A549 cells were treated with ECAP for 24 h, tripsinized and centrifuged for 3 
min at 2000 xg. The resulting pellet was re-suspended in 200 µl 0.1 M PBS. 
To each 100 µl A549 cell suspension, 100 µl of Annexin staining buffer and 
100µl of Annexin-V-Fluos labelling solution (1 ml Annexin staining buffer + 20 
µl annexin-V + 20 µl propidium iodide) were added in 1.5 ml Eppendorfs. The 
BD Accuri™ C6 flow cytometer and software was used for analysis and 
capturing of data elucidated by stained cells. Cells were gated using FlowJo 
v7.1 software (Tree Star Inc., Ashland, USA). About 50 000 events were 
analysed in triplicate. The obtained results were expressed as percentage of 
apoptotic cells.   
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2.1.10. Statistical analysis 
 
GraphPad Prism v5.0 software (GraphPad Software Inc., La Jolla, USA) was 
used for statistical analysis. For all experiments, the obtained results of the 
triplicates were represented as means with standard deviation (SD).  
The statistical significance of the results was analysed with unpaired t-test 
and a 95% confidence interval. The values of p < 0.05 were then considered 
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CHAPTER THREE 
3.1. RESULTS 
3.1.1. Synthesis of (Z)-4-((9-ethyl-9H-carbazol-3-yl)amino)pent-3-en-2-one 
(ECAP) 
 
The resulting product was a yellow solid produced in 94 % yield; melting point 
(mp): 240-247 °C. Functional groups were predicted using IR (KBr, cm-1): 
1774.97 (C=O), 3043.92 (N-H), 2988.76 (C-H) Alkanes, 1562.66 (C=C) 
Aromatic rings (Figure 19.A). The 1H-NMR (400 MHz, CDCl3) was used to 
predict the ratio of the hydrogen number: δ (ppm) 12.59 (s, 1H), 8.20 (q, 1H), 
7.8 (d, 1H), 7.45–7.40 (m, 2H), 7.35–7.30 (m, 3H), 5.3 (s, 1H), 4.35 (q, 2H), 
2.25 (s, 3H) 1.95 (s, 3H), 1.45 (t, 3H) (Figure 19.B). The 13C-NMR (400 MHz, 
CDCl3) was further used to predict the backbone of the molecule: δ (ppm) 
195.67, 191.20, 161.94, 140.51, 138.18, 130.13, 126.39, 126.18, 123.93, 
123.15, 122.47, 121.00, 120.52, 119.00, 117.65, 109.32, 108.72, 108.59, 
96.60, 37.70, 29.08, 27.84, 19.80, 13.82, 13.72 (Figure 19.C).   
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Figure 18: Characterization of the novel (Z)-4-((9- ethyl-9H-carbazol-3-yl)amino)pent-3-en-2-
one (ECAP) using A) IR, B) 1H-NMR and C) 13C-NMR spectrums. 
 
3.1.2. Cell viability assay 
 
The MTT assay was used to determine the anti-proliferative effect of ECAP on 
the A549 lung cancer cells. An IC50 value of 0.565 µg/ml at 95% confidence 
interval was calculated (Figure 20) and subsequently used in all assays.  
C 
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Figure 19: Dose-response curve showing cytotoxic effect of ECAP on A549 lung cancer cell 
line after 24 h treatment. 
Figure 2 demonstrated a decrease in cell viability with increasing 
concentration. 
 
3.1.3. Lipid peroxidation assay for quantification of malondialdehyde 
(MDA).  
 
Lipid peroxidation, as measured by the MDA concentration, was significantly 
increased in ECAP treated cells compared to the control (0.305 ± 0.00490 µM 
vs 0.190 ± 0.007479 µM (control)) at 95% confident interval (Figure 21).  
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Figure 20: The effect of ECAP on lipid peroxidation on A549 lung cancer cells after 24 h 
incubation. (p < 0.0002) [*** significance compared to the control, number of replicates: n > 3] 
 
3.1.4. DNA damage  
 
DNA damage was assessed using the comet assay. ECAP significantly 
increased the length of comet tails in treated cells compared to the control 
with 81.80 ± 1.19 µm vs 68.20 ± 1.61 µm (control) (Figure 22).  
 
Figure 21: Comet assay showing DNA damage in A549 cells after 24 h treatment with A) 
Control and B) ECAP. (p < 0.0001) 
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3.1.5. Western blot analysis 
 
Western blotting was used to determine apoptotic proteins induced by ECAP 
in A549 lung cancer cells. Nrf2/Keap1 system regulates the expression of 
proteins such as SOD and heat shock proteins which are involved in the 
cellular antioxidant and anti-inflammatory defense (Petri et al., 2012). ECAP 
significantly down regulated the expression of Nrf2 (p < 0.02*) resulting in a 
subsequent down regulation of Hsp70 (p < 0.02*) and SOD (p < 0.01**) 
(Figure 23). ECAP was further observed to activate the expression of pro-
apoptotic proteins such as p53 (p < 0.09) and Bax (p < 0.25) and down 
regulated the anti-apoptotic Bcl-2 (p < 0.0006***) (Figure 23).  
 
 
Figure 22: The effect of ECAP on the expression of Bax, Bcl-2, p53, Nrf2, Hsp70 and SOD. 
Western blot analysis demonstrated an increase in band density of p53 and 
Bax compared to the control, while a decrease in band density was observed 
for Bcl-2, Hsp70, SOD and Nrf2 compared to the control.  
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3.1.6. Caspase-3/7, 8, 9 and ATP activities 
 
Caspases are ATP dependent enzymes that promote apoptosis. The effects 
of ECAP on the activity of caspases and ATP levels were measured in A549 
lung cancer cells (Table 1) 
 
Table 1: Caspases and ATP levels in ECAP treated A549 cells after 24hr 
treatment. 
 Mean ± SD (RLU × 104)   
 Control ECAP Fold change p-value 
Caspase-3/7 1.831 ± 394.7 2.895 ± 1265 1.471 0.0029** 
Caspase-8 67.220 ± 2927 76.930 ± 5513 1.144 0.0001*** 
Caspase-9 34.440 ± 10760 54.980 ± 6295 1.601 0.0001*** 
ATP 305.100 ± 35420 272.500 ± 42010 0.894 0.0040** 
*denotes statistically significance with respect to the control and uncertainties represent 
standard deviation (SD) from the means. Number of replicates: n > 3. ** p < 0.001, *** p < 
0.0001 
Table one demonstrated a significant increase in caspase and ATP activity of 
ECAP treated A549 cells compared to the control. Caspase-9 had a higher 
fold change compared to caspase-8. 
 
3.1.7. Annexin-V-Fluos assay 
 
Translocation of the membrane PS is one of the markers of the early stages 
of apoptosis. Figure 24 demonstrated that treatment with ECAP significantly 
induced apoptosis in A549 lung cancer cells (50.4 ± 0.44%) compared to the 
control (25.1 ± 0.34%).  
 

















Figure 23: The effect of ECAP on the induction of apoptosis of A549 cells after 24 h 


















The results of this study demonstrated the ability of ECAP to induce reduction 
in cell viability, to elevate lipid peroxidation, to induce DNA damage as well as 
its effect on PS externalization in A549 lung cancer cells. Moreover ECAP 
was observed to induce reduction in the expression of Nrf2, SOD, Hsp70 and 
Bcl-2 and overexpression of p53 and Bax in treated cells. Activation of ATP, 
caspase-3/7, -8 and -9 activity was also observed in the presence of ECAP.  
 
Based on their reported biological properties, an increased research interest 
has been driven towards studying the anticancer properties of carbazoles and 
their synthetic analogs. The cytotoxic activity of carbazoles and some of their 
analogs has been previously demonstrated on various cancer cell lines 
including lung, leukaemia and pancreatic cells (Mohan et al., 2013, Laronze et 
al., 2005, Mandal et al., 2012). The results of this study demonstrated the 
ability of the novel synthesized carbazole compound to induce cytotoxicity on 
A549 lung cancer cells (Figure 20).  
 
Anticancer therapies such as chemotherapy and radiotherapy make use of 
ROS overproduction to inhibit the proliferation of cancer cells (Renschler, 
2004). The TBARS assay data demonstrated that ECAP also induces ROS 
production, whereby a significant elevation of MDA concentration 
corresponded with an increase in lipid peroxidation (Figure 21).  
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Lungs are highly organized organs, which play an important role in 
mammalian respiration.  
 
Lungs have elevated levels of Nrf2, which makes them resistant to ROS 
generated during gas exchange.  Nrf2 is the primary antioxidant response 
regulatory protein which translocate to the nucleus upon oxidative damage, 
where it promote transcription of antioxidant proteins such as SOD as well as 
the transcription of Hsp70 (Nguyen et al., 2009, Zoja et al., 2014, Kansanen et 
al., 2013, Velichkova and Hasson, 2005). Elevated Nrf2 levels have been 
reported in various cancer cell lines including A549 lung cancer cells. Nrf2 
overexpression in lung cancer cells account for their resistance and 
metastasis thus making lung cancer therapy difficult.  
 
There is a need for development of novel anticancer compounds that are able 
to reduce Nrf2 expression in lung cancer. Therefore, the effect of ECAP on 
Nrf2 expression was determined. Western blot data demonstrated a reduction 
in Nrf2 expression in the presence of ECAP (Figure 23). This might possibly 
mean that ECAP induced the activity of Keap-1, which then targeted Nrf2 for 
ubiquitin-mediated degradation. Hence the observed down-regulation of the 
expression of Nrf2 in the presence of ECAP could then explain the reduced 
levels of the expressed Hsp70 and SOD in A549 lung cancer cells (Figure 
23). This resulted in the observed induced lipid peroxidation, which was due 
to ROS overproduction as measured by elevated MDA concentration.  
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Down regulation of antioxidant proteins is associated with ROS 
overproduction and induction of chronic oxidative damage on biomolecules 
such as DNA, proteins and lipids (Li et al., 2011). Therefore in addition to the 
detected high levels of MDA, ECAP was observed to significantly induce DNA 
damage in A549 cell as demonstrated by high intensity and longer lengths of 
comet tails (Figure 22).  
 
The observed chronic oxidative DNA damage in comet assay could have 
resulted in the increased overexpression of serine 46 phosphorylated p53 in 
ECAP treated A549 lung cancer cells (Figure 23). This is simply because it 
has been reported that DNA damage can activate p53 protein phosphorylation 
at serine 46 residue resulting in cell cycle arrest and subsequent DNA repair 
(Bai and Zhu, 2006). The western blot data further demonstrated Bax 
activation and down-regulation of Bcl-2 expression in the presence of ECAP 
(Figure 23). This could mean DNA damage was beyond repair, for this reason 
the activated p53 induced cell death through activation of pro-apoptotic 
proteins and down-regulation of anti-apoptotic proteins. As a result this makes 
ROS-mediated DNA damage to be an essential therapeutic target for cancer 
treatment.  
 
Bax activation is reported to induce mitochondrial polymerization thereby 
disrupting the electron transport chain (ETC). Therefore, ATP levels were 
measured to study the effect of the compound on mitochondrial integrity.  
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The previous work by Roy and co-workers (2005) demonstrated mehanine, 
the carbazole alkaloid to depolarize the mitochondrial membrane of U937 
cells resulting in 60-40% reduction on cellular ATP level compared to the 
control. In light of this discovery, a significant 0.894 fold decrease in cellular 
ATP level with respect to the control in A549 lung cancer cells was observed 
in the presence of ECAP (Table 1). This could mean that just like mahanine, 
the novel carbazole compound depolarized the mitochondrial membrane of 
A549 lung cancer cells resulting in cytochrome c release and the subsequent 
activation of caspase-9. 
 
So far the data demonstrated the cytotoxicity of ECAP in A549 lung cancer 
cells to be associated with its ability to induce ROS overproduction, which 
resulted in lipid peroxidation and DNA damage, thus activating the expression 
of tumour suppressor proteins such as p53. Accordingly, in order to further 
stipulate the mechanism of action of this novel carbazole compound, 
luminometry was used to assess the effect ECAP on the activity of the 
caspases. Caspases are the excussioner molecules involved in both the 
extrinsic and the mitochondrial dependent pathways of apoptosis.  
 
Mahanine, a carbazole alkaloid isolated from Micromelum minutum has been 
reported to induce apoptosis through a mitochondrial dependent pathway 
(Kagan et al., 2002, Roy et al., 2005), therefore a significant higher fold 
change of 1.601 (caspase-9) compared to that of 1.144 (caspase-8) 
demonstrated ECAP to also mainly execute apoptosis of lung cancer cells 
through the intrinsic-mitochondrial pathway (Table 1).  
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ECAP treated cells also demonstrated an induced caspase-3/7 activity (1.471 
fold change). The caspase activity data might be due to that activation of 
executioner caspases activated the initiator caspases-3/7 resulting in down-
stream cleavage of proteins such as poly(ADP-ribose) polymerase (PARP) 
thus inducing apoptosis of A549 lung cancer cells. 
 
As mentioned earlier, PS externalization is an early marker of apoptosis, 
therefore a higher percentage of PS detected in treated cells compared to the 
control during Annexin V staining further demonstrated the anticancer 
properties of ECAP to be associated with its ability to induce apoptosis of 
A549 lung cancer cells. Up to this far it is evident that this novel carbazole 
compound comprises of unique properties rendering ECAP as a potential 
antiproliferative agent towards A549 lung cancer cells. Therefore both the 
caspase activity and Annexin-V data could mean that ECAP activated an 
intrinsic mitochondrial-mediated apoptosis of cultured lung cancer cells 
through activation of executioner the Caspase-9 which activated the initiator 
caspases-3/7 thereby resulting in down-stream cleavage of proteins such as 
PARP. 
 
The results of this study demonstrated that the cytotoxic properties of (Z)-4-[9-
ethyl-9aH-carbazol-3-yl) amino] pent-3-en-2-one could possibly be associated 
with its ability to down regulate the expression of antioxidant defense proteins 
(Nrf2 and SOD) and Hsp70 thus activating ROS overproduction. This ROS 
overproduction induced DNA damage, which up-regulated the expression of 
tumor suppressor proteins such as p53.  
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p53 activation down-regulated the expression of Bcl-2 thus activating the 
expression of Bax. Bax activation therefore resulted in mitochondrial 
polymerization and the release of cytochrome c as evidenced by a decrease 
in cellular ATP levels. The released cytochrome c then activated caspase-9, 
which subsequently resulted in activation of caspae-3/7 thus inducing a 
mitochondrial-mediated apoptosis of A549 lung cancer cells.  
 
However this was an in vitro study, therefore more work still need to be done 
in order to authenticate the cytotoxic pathway of ECAP on A549 lung cancer 
cells. Therefore it might be too early to conclude that ECAP induced 
cytotoxicity on A549 lung cancer cells through an apoptotic pathway. As a 
result in order to prove that ECAP induced apoptosis of cultured lung cancer 
cells more experiments such a Jc-1 stain and Hoechst stain should be carried 
out. It has been reported that one of the major challenges associated with 
development of anti-cancer drugs is the ability to develop highly effective 
drugs which are specific for cancer cells and have a little or no side effects on 
normal mammalian cells.  
 
Cancer cells are characterized by mitochondrial dysfunction and increased 
metabolic activity making cancer cells to have higher ROS level compared to 
non-cancer cells. This excessive ROS production can result in increased 
cancer cell sensitivity thus functioning as tumour suppressors. Therefore the 
ability of ECAP to suppress Nrf2, SOD and Hsp70 activity in A549 lung cancer 
cells can result in ROS overproduction rendering this novel compound to be 
more specific to cancer cells.  
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As mentioned earlier in the literature review carbazole compounds and their 
derivatives are able inhibit cancer proliferation through DNA intercalation and 
inhibition of DNA topoisomerase II activity (Nandy et al., 2014). However, both 
cancer and non-cancer cells have DNA and DNA topoisomerase II, therefore 
ECAP might induce DNA intercalation and inhibit DNA topoisomerase II in 
both cancer and non-cancer cells.  
Thus the specificity of ECAP should be determined using different cancer cell 
lines as well as using non-cancer cells.  
 
There is also need to determine the effect of ECAP on epigenetic changes 
and microRNA expression on lung cancer cells. After a proper in vitro 
characterization of ECAP on A549 lung cancer cells and other cancer and 
non-cancer cell lines, animal models should then be introduced for further 
characterization of the effects of this novel synthesized carbazole compound 















The study demonstrated the anticancer properties of ECAP to be due to its 
ability to induce p53 mediated apoptosis on lung cancer cells through 
activation of oxidative stress, hence down-regulating the expression of anti-
apoptotic proteins and antioxidant defense proteins. This resulted in DNA 
damage and subsequent up-regulation of tumour suppressor genes, pro-
apoptotic proteins and apoptosis executioner molecules (Figure 25).  
 
 
Figure 24: A schematic summary of apoptotic pathway of a novel cabazole compound (Z)-4-
[9-ethyl-9aH-carbazol-3-yl) amino] pent-3-en-2-one on A549 lung cancer cells. 
 
This work therefore show the novel carbazole compound (Z)-4-[9-ethyl-9aH-
carbazol-3-yl) amino] pent-3-en-2-one to possess potential pharmaceutical 
properties as an alternative treatment for lung cancer. However, since this 
was an in vitro study, more work still need to be done to further characterize 
this novel compound and to fill in the gaps in the postulated pathway of action, 
as well as to analyze its specificity.  
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Future work will include monitoring the effect of methylation of ECAP on 
epigenetic changes and its effect on histones and microRNA expression. Its 
specificity will also need be studied using different cancer and non-cancer cell 
lines. After a proper in vitro characterization of ECAP, animal models can then 
be introduced to help to further characterize this novel compound to get a 
broader picture of its mode of action and its side effects. The structure of the 
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SUPPLEMENTARY MATERIAL 
S1: These supplementary materials represent data for figure 6: Western blots 
showing the effect of ECAP on the expression of Bax, Bcl-2, p53, Nrf2, Hsp70 
and SOD. 
Mw: Molecular marker 
C1 and C2: Controls 
V1 and V2: Vehicle controls 
T1 and T2: treatments with ECAP 
For the basis of data presentation in the results section of the paper, as well 
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S2: Represent the luminometry data 
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